research Formulation, Evaluation and Stability Studies of Dutasteride Loaded Niosomal Gel
The gel effectively delivers dutasteride for hair loss treatment and remains stable for 90 days.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Evaluation of Dutasteride-Loaded Liposomes and Transfersomes for Follicular-Targeting for Androgenic Alopecia Topical Treatment
Transfersomes are better than liposomes for targeting hair follicles in alopecia treatment.
research Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
Dutasteride helps hair growth in those unresponsive to finasteride, but may cause more sexual dysfunction.
research Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know
Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
research Reply to: Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia – There is insufficient evidence to recommend dutasteride as first‐line treatment in frontal fibrosing alopecia
research Bicalutamide in Dermatology: A Narrative Review
Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
research Flurandrenolide
research 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia
Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
research Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
research Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia
Oral dutasteride is effective and safe for treating frontal fibrosing alopecia.
research Actualización en el tratamiento de la tricotilomanía
N-acetylcysteine and memantine are recommended as safe and effective treatments for trichotillomania.
research MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOSAL VENO-OCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOSAL FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOSAL NERVE INJURY
Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
research Cutting Costs, Not Care: New Models for Affordable Men’s Health Medications
CPDC offers significant cost savings on men's health medications compared to Medicare and GoodRx.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research Optimization, characterization, and follicular targeting assessment of tretinoin and bicalutamide loaded niosomes
The niosomes effectively target hair follicles for acne treatment.
research Finasteride
research Finasteride
research THERAPEUTIC HOTLINE: Effectiveness of the association of cetirizine and topical steroids in lichen planus pilaris - an open-label clinical trial
Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.
research Effect ofCuscuta reflexaRoxb on androgen-induced alopecia
Cuscuta reflexa extract may help treat hair loss caused by hormones.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research METYRAPONE AS A BRIDGING THERAPY IN FLORID CUSHING’S DISEASE PATIENT PRIOR TO PITUITARY ADENOMECTOMY
Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
research Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia
Iron oxide nanoparticles improve skin penetration and drug release for hair loss treatment.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Efficacy of dutasteride on androgenetic alopecia recalcitrant to finasteride
research EFFECT OF A COMBINATION OF DUTASTERIDE AND PARENTERAL TESTOSTERONE UNDECANOATE ON TESTOSTERONE DEFICIENCY SYMPTOMS AND PROSTATE IN PATIENTS WITH TESTOSTERONE DEFICIENCY AND BENIGN PROSTATIC HYPERPLASIA
The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
research Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.